Institute of Digestive Health and Liver Diseases, Mercy Medical Center, Baltimore, MD.
Departments of Surgery and Medicine, University of Maryland School of Medicine, Baltimore, MD.
Transplantation. 2019 Jan;103(1):113-121. doi: 10.1097/TP.0000000000002355.
Patients with nonalcoholic steatohepatitis (NASH) cirrhosis have excellent postliver transplant survival despite having many comorbidities. We hypothesized that this could be due to a selection bias.
We analyzed the United Network for Organ Sharing data from 2002 to 2016 and compared postliver transplant survival of NASH (n = 7935) patients with cryptogenic cirrhosis (CC) (n = 6087), alcoholic cirrhosis (AC) (n = 16 810), and autoimmune hepatitis cirrhosis (AIH) (n = 2734).
By 3 years of listing, the cumulative incidence (CI) of death or deterioration was 29% for NASH, 28% for CC and AC, and 24% for AIH, but when adjusted for risk factors, the CI was similar for NASH and AIH. The factors that increased the risk of waiting list removal due to death/deterioration were poor performance status, encephalopathy, diabetes, high Model for End-stage Liver Disease, Hispanic race, older age and a low serum albumin. Most patients were transplanted within the first year (median, 2 months; interquartile range, 1-7 months) of listing and by 5 years, the unadjusted CI of transplantation was 54% for NASH, 52% for CC, 51% for AIH, and 48% for AC. The adjusted CI of transplantation within 2 months of listing was higher for AC (subhazard ratio [SHR], 1.17), AIH (SHR, 1.17), and CC (SHR, 1.13) when compared with NASH, but after 2 months, adjusted transplantation rates decreased in AC (SHR, 0.6), AIH (SHR, 0.78), and CC (SHR, 0.95). The negative predictors of receiving a transplant were dialysis, female sex, nonwhite race, high albumin, and creatinine.
Patients with NASH cirrhosis are not disadvantaged by higher waitlist removal or lower transplantation rates.
尽管非酒精性脂肪性肝炎(NASH)肝硬化患者合并多种并发症,但他们在肝移植后的存活率非常高。我们假设这可能是由于选择偏倚造成的。
我们分析了 2002 年至 2016 年期间美国器官共享网络的数据,并比较了 NASH(n=7935)患者、隐源性肝硬化(CC)(n=6087)患者、酒精性肝硬化(AC)(n=16810)患者和自身免疫性肝炎肝硬化(AIH)(n=2734)患者的肝移植后存活率。
在列入名单的 3 年内,NASH、CC 和 AC 的累积死亡率或病情恶化率分别为 29%、28%和 24%,但调整风险因素后,NASH 和 AIH 的死亡率相似。导致等待名单因死亡/恶化而移除的风险因素包括较差的身体状况、肝性脑病、糖尿病、较高的终末期肝病模型评分、西班牙裔、年龄较大和血清白蛋白较低。大多数患者在列入名单后的 1 年内(中位数为 2 个月;四分位距为 1-7 个月)接受了移植,并且在 5 年内,NASH、CC、AIH 和 AC 的未调整移植累积发生率分别为 54%、52%、51%和 48%。与 NASH 相比,AC(亚危险比 [SHR],1.17)、AIH(SHR,1.17)和 CC(SHR,1.13)在列入名单后 2 个月内的移植 SHR 更高,但 2 个月后,AC(SHR,0.6)、AIH(SHR,0.78)和 CC(SHR,0.95)的调整移植率下降。接受移植的负面预测因素包括透析、女性、非白种人、高白蛋白和肌酐。
NASH 肝硬化患者不会因较高的移出等待名单率或较低的移植率而处于不利地位。